2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Breast Neoplasms
20
Prostatic Neoplasms
7
Triple Negative Breast Neoplasms
6
Ovarian Neoplasms
4
Neoplasm Metastasis
4
Melanoma
3
Lymphoma
3
Lung Neoplasms
3
Hematologic Neoplasms
3
Endometrial Neoplasms
3
Uterine Cervical Neoplasms
2
Recurrence
2
Neoplasms
2
Multiple Myeloma
2
Locally Advanced (Inoperable) or Metastatic Breast Cancer
2
Leukemia
2
Healthy Participants
2
Disease Progression
2
Carcinoma, Non-Small-Cell Lung
2
Uterine Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumour
1
Rectal Neoplasms
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Interventions
Rituximab
301
Cyclophosphamide
241
Peripheral Blood Stem Cell Transplantation
115
fludarabine phosphate
111
Filgrastim
93
Etoposide
85
Radiotherapy
81
Lenalidomide
81
Vincristine
79
Prednisone
79
Mycophenolic Acid
67
Doxorubicin
62
Whole-Body Irradiation
59
Cyclosporine
59
Bendamustine Hydrochloride
59
Melphalan
57
Tacrolimus
54
Busulfan
52
obinutuzumab
50
fludarabine
50
Cytarabine
49
Methotrexate
45
Antilymphocyte Serum
43
Bortezomib
42
Methylprednisolone
37
Carmustine
37
sargramostim
36
ibritumomab tiuxetan
33
ibrutinib
30
Dexamethasone
30
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma, Follicular
×
capivasertib
×
Clear all
NCT05008055
2024-12-20
CAPITAL
AstraZeneca
Phase 2
Completed
30 enrolled
15 charts